

## RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE

### The underestimated issue of non-reproducible cardiac troponin I and T results

Favresse, Julien; Bayart, Jean Louis; Gruson, Damien; Bernardini, Sergio; Clerico, Aldo; Perrone, Marco

*Published in:*  
Clinical Chemistry and Laboratory Medicine

*DOI:*  
[10.1515/cclm-2020-1564](https://doi.org/10.1515/cclm-2020-1564)

*Publication date:*  
2021

*Document Version*  
Publisher's PDF, also known as Version of record

#### [Link to publication](#)

*Citation for published version (HARVARD):*  
Favresse, J, Bayart, JL, Gruson, D, Bernardini, S, Clerico, A & Perrone, M 2021, 'The underestimated issue of non-reproducible cardiac troponin I and T results: Case series and systematic review of the literature', *Clinical Chemistry and Laboratory Medicine*, vol. 59, no. 7, pp. 1201-1211. <https://doi.org/10.1515/cclm-2020-1564>

#### General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

#### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

## Review

Julien Favresse\*, Jean-Louis Bayart, Damien Gruson, Sergio Bernardini, Aldo Clerico and Marco Perrone

# The underestimated issue of non-reproducible cardiac troponin I and T results: case series and systematic review of the literature

<https://doi.org/10.1515/cclm-2020-1564>

Received October 21, 2020; accepted December 23, 2020;

published online January 12, 2021

**Abstract:** Cardiac troponins (cTn) are the preferred biomarkers for the evaluation of myocardial injury and play a key role in the diagnosis of acute myocardial infarction (MI). Pre-analytical or analytical issues and interferences affecting troponin T and I assays are therefore of major concern given the risk of misdiagnosis. False positive troponin results have been related to various interferences including anti-troponin antibodies, heterophilic antibodies, or elevated alkaline phosphatase level. On the other hand, false negative results have been reported in the case of a large biotin intake. These interferences are characterized with erroneous but reproducible troponin results. Of interest, non-reproducible results have also been reported in the literature. In other words, if the sample is reanalyzed a second time, a significant difference in troponin results will be observed. These interferences have been named “fliers” or “outliers”. Compared to the biotin interference that received major attention in the literature, troponin outliers are also able to induce harmful clinical consequences for the patient. Moreover, the prevalence of outliers in recent

studies was found to be higher (0.28–0.57%) compared to the biotin interference. The aim of this systematic review is to warn clinicians about these non-reproducible results that may alter their clinical judgment. Four case reports that occurred in the Clinique of Saint-Luc Bouge are presented to attest this point. Moreover, we aimed at identifying the nature of these non-reproducible troponin results, determining their occurrence, and describing the best way for their identification.

**Keywords:** flyer; outlier; patient safety; prevalence; troponin.

## Introduction

Cardiac troponins (cTn) are the preferred biomarkers for the evaluation of myocardial injury and play a key role in the diagnosis of acute myocardial infarction (MI) [1]. Some pre-analytical or analytical issues and interferences leading to false positive or false negative could therefore have harmful clinical consequences for the patient.

## Case report 1

On May 2019, an 80-year-old female went to her general practitioner (GP) to get a blood test for diabetes control. The patient is known with heart failure, hypertension, hypercholesterolemia, and hypertriglyceridemia and complained about chronic retrosternal pain since several months. The patient was sent to our emergency department (ED) based on an increased high-sensitivity cardiac troponin T (hs-cTnT) concentration (102.0 ng/L; 99th upper reference limit [RL] = 14.0 ng/L; Roche Diagnostics, Basel, Switzerland). Creatine kinase-MB isoenzyme (CK-MB, immunological; Roche Diagnostics) and N-terminal pro B-type natriuretic peptide (NT-proBNP; Roche Diagnostics) were 3.4 µg/L (RL <4.9 µg/L) and 557 pg/mL (RL <486 pg/mL), respectively. Fifteen years ago, the patient was diagnosed with transient

---

\*Corresponding author: **Julien Favresse**, Department of Laboratory Medicine, Clinique Saint-Luc Bouge, 8 Rue Saint-Luc, 5000 Bouge, Belgium; and Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Namur, Belgium, Phone: +32 (0)81 20 91 44, E-mail: j.favresse@labstluc.be

**Jean-Louis Bayart**, Department of Laboratory Medicine, Cliniques Saint-Pierre, Ottignies, Belgium

**Damien Gruson**, Department of Laboratory Medicine, Cliniques Universitaires Saint-Luc et Université Catholique de Louvain, Woluwé-Saint-Lambert, Bruxelles, Belgium

**Sergio Bernardini**, Department of Clinical Biochemistry and Clinical Molecular Biology, University of Rome Tor Vergata, Rome, Italy

**Aldo Clerico**, CNR-Regione Toscana G. Monasterio Foundation, Heart Hospital, Massa, Italy; and Scuola Superiore Sant’Anna, Pisa, Italy

**Marco Perrone**, Department of Cardiology, University of Rome Tor Vergata, Rome, Italy

ischemic attack. Her familial history revealed fatal MI by her father, five uncles and aunts. Her brother also died from stroke. A new blood sample was drawn in the ED 5 h after the first one, and a significant hs-cTnT drop was observed (15.1 ng/L). Based on this large difference, the first sample drawn by the GP was re-assayed in our laboratory and near normal hs-cTnT result was obtained (14.4 ng/L). The sample drawn in the ED was also re-assayed and gave somewhat similar results (14.0 ng/L). Electrocardiogram (ECG) was performed and was characterized with left bundle branch block. The patient was admitted to the cardiology service where a coronary angiography was performed and a pharmacological stent was placed. The first result (102.0 ng/L) was considered to be a false positive and non-reproducible result.

### Case report 2

On December 2019, a 53-year-old man was seen by his GP for a follow-up visit, owing to slight chest discomfort. The patient was known with hypercholesterolemia and hypertension. Based on the clinical presentation, the GP ordered a cTn test. A few hours later, our laboratory called the GP because of the elevated hs-cTnT (84.0 ng/L, 99th percentile of the assay = 14.0 ng/L). Although creatine kinase (CK) and CK-MB were both elevated (301 U/L; RL <190 and 7.7 µg/L; RL <4.9 µg/L, respectively), the CK-MB index (CK-MB\*100/CK) was negative (2.6; RL <3.5). In light of this information, the GP decided to refer the patient to the ED. There, a new sample was taken and a normal hs-cTnT result was obtained (6.8 ng/L). CK-MB was still increased (8.6 µg/L) and the CK-MB index was still negative (2.7). The first sample was subsequently measured again, which returned a normal hs-cTnT result (5.3 ng/L). The patient's ECG, echocardiography, and stress test were all normal. For this patient, hs-cTnT was, thus, falsely elevated. Fortunately, the incorrect result did not lead to any unneeded invasive procedures [2].

### Case report 3

On December 2019, a 65-year-old man with known chronic obstructive pulmonary disease was hospitalized for a respiratory tract infection. C-Reactive Protein (CRP) and neutrophils count were both elevated (224 mg/L; RL <5 mg/L and  $11.0 \times 10^3/\mu\text{L}$ ; reference interval  $2.0\text{--}7.5 \times 10^3/\mu\text{L}$ , respectively). The patient's hs-cTnT was also substantially elevated (393.0 ng/L). Three hours later, a new sample was taken, and normal results were obtained (10.3 ng/L). Both samples were measured again, which returned normal

results (12.0 and 13.0 ng/L, respectively). CK-MB and NT-proBNP were both normal, and the ECG revealed no abnormalities. For this patient, hs-cTnT was thus again falsely elevated. Fortunately, the incorrect result did not lead to any unneeded invasive procedures [2].

### Case report 4

On September 2020, a 43-year-old man was seen by his GP for intermittent chest pain. The patient is known with Behçet's disease and takes ciclosporin. The patient was sent to our ED based on an increased hs-cTnT concentration (42.3 ng/L) performed at our laboratory. However, ECG and echocardiography investigations were both normal in this patient. A new blood sample was drawn in the ED 4 h after the first one, and a significant drop in the measured hs-cTnT level was observed (10.8 ng/L). Based on this large difference, the first sample drawn by the GP was re-assayed in our laboratory and a normal hs-cTnT result was obtained (11.8 ng/L). The sample drawn in ED was also re-assayed and gave similar results (12.0 ng/L).

Based on the observation of these discordant results, we checked the precision of our hs-cTnT assay at several occasions. Using patient pools, coefficient of variations near the decision level (i.e., 14 ng/L) ranged from 2.3 to 3.9%. Roche Diagnostics also checked our analytical process and did not identify any failure. Of note, the four cases abovementioned occurred on three different reagent lots.

### Interferences in troponin assays

False positive cTn results have been related to the presence of anti-cTn antibodies or immunocomplexes [3, 4], heterophilic antibodies [5], elevated alkaline phosphatase level [6], contrast media [7], instrument malfunction [8], or carry-over [9]. False negative results with cTn assay may also be observed in the case of a large biotin intake [10, 11]. All these interferences are characterized with erroneous but reproducible cTn results: in other words, if the sample is reanalyzed a second time, the same erroneous result will occur [12, 13]. Non-reproducible (also named irregular) interferences have also been reported in the literature [14]: in this case, if the sample is reanalyzed a second time, a significant difference in cTn results will be observed. These interferences have been described as "fliers" or "outliers" [14]. In this review, we decided to use the term "outlier". It is well known that the irregular analytical errors due to interferences in immunoassay systems are not only variable and sporadic but also clinically misleading because

they can lead to both false-positive and false-negative results [14]. The aim of this review is to warn clinicians and medical laboratory scientists about these non-reproducible results that may alter the clinical judgment. Moreover, we aimed at identifying the nature of these non-reproducible cTn results, determining their occurrence, and describing the best way for their identification.

## Systematic review of the literature

For systematic analysis of the literature about non-reproducible cardiac cTn results (cTnI, cTnT, hs-cTnI, hs-cTnT), we carried out a systematic electronic search on PubMed and Scopus without date restriction. The following keywords were used: “outlier” or “flier” or “flyer”, or “non-reproducible”, in combination with “troponin”. The electronic search according to the established criteria identified 39 items on PubMed and 44 items on Scopus. Abstract and/or full texts not directly reporting data about non-reproducible cTn results on both searchable databases were excluded. Eleven articles have been included. The bibliographic references of the selected articles published in English and French were reviewed for additional relevant studies and 15 additional studies were included. All the articles identified according to these search criteria were systematically assessed by two authors (JF and JLB). Overall, 26 studies published between 1997 and 2020 were finally included for review.

## Nature of these outliers

It has been suggested that the nature of these non-reproducible results could be related to the presence of fibrin in serum or plasma. The proposed mechanism is that fibrin may cross-link the assay antibodies to produce false positive cTn results [15]. Under optimal clotting conditions, the serum does not contain fibrinogen, fibrin, or blood cells [16]. In case of latent or incomplete removal during centrifugation, residual fibrin may interfere with the assay [17]. Of note, the plasma still contains fibrinogen because clot formation has been prevented by the presence of anticoagulants during blood collection [16]. The main advantage of using plasma is the reduced turn-around time (TAT) since the samples can be centrifuged without any delay, as compared to serum [16]. However, appropriate mixing of the blood tube after phlebotomy is mandatory to ensure that the anticoagulant has been adequately mixed [18]. In case of ineffective mixing, or in plasma samples stored at 2–8 °C during more than 24 h, fibrin is formed from

fibrinogen and may also interfere with the assay [15, 19]. However, the fact that fibrin is the source of such non-reproducible results is mostly speculative. Only Sheehan et al. [20] and Dimeski et al. [15, 21] proved that fibrin caused a positive interference on a limited number of plasma samples. Kazmierczak et al. showed that fibrin was visible in seven serum samples out of 24 for which non-reproducible results were noted [22]. Up to now, the clear nature of these outliers are not known [23, 24], even if some pre-analytical variables cannot be excluded. Therefore, the nature of outliers is categorized as unknown in several studies [3, 12, 13, 24–29]. Recently, the nature of some non-reproducible cTn results was found to be due to magnetic/paramagnetic particles contamination, which occurred during the reagent filling process by the manufacturer and was specific to a particular reagent lot [2].

## Definition of an outlier

There is no unique way to identify an outlier using statistical procedures. Nevertheless, three main statistical approaches have been suggested in the literature. First, results are identified as outliers when the difference between the two results exceeded a specified z score value ( $\text{result 1} - \text{result 2} / \sqrt{SD_1^2 + SD_2^2}$ ), with a very high probability (i.e.,  $p=0.0005$  for  $z=3.48$ ) [23]. Second, when the difference exceeded a critical difference (CD) defined by the formula  $CD = z \times \sqrt{2} \times SD_{\text{Analytical}}$  [12, 13, 24].  $SD_A$  equivalent to a fixed 10% CV or derived from internal quality controls were both used. Third, critical number of outliers has also been used. A critical outlier is a false value (identified using the CD formula) potentially affecting the clinical decision (i.e., the first hs-cTnT result  $> 14.0$  ng/L, while the second hs-cTnT result  $< 14.0$  ng/L) [13, 24]. The detection of a critical outlier will therefore more likely lead to harmful clinical consequences compared to a non-critical outlier. Since the second result is an analytical repeat on the same analyzer, no biological or preanalytical variation is needed to be included in the calculation [12]. Less widely used outlier definition included a difference of two SD [30], a difference of 30% [31], or 45% [22]. Some authors did not disclose a clear outlier definition [19, 20, 32–34].

## Procedures to identify outliers

Two methods have been used to identify non-reproducible cTn results in the literature: (1) recentrifuging the samples or (2) repeat testing without recentrifuging the sample.

## Identification through recentrifugation

Studies that used the recentrifugation method to identify outliers are present in Table 1. Grossly, the outlier rate varied from 0.17 to 28.57% in serum and from 0.091 to 4.0% in plasma. Outlier definition varied widely between studies. For example, Li et al. described that a difference of 30% was sufficient [31], while a difference of two SD was required for Fleming et al. [30]. Some studies did not report a clear outlier definition [3, 19, 20]. Hejl et al. defined that an original result above 100 ng/L and below 100 ng/L after recentrifugation was a false positive result [32]. However, this approach does not take into account assay imprecision, and so the number of false positive samples may be grossly overestimated [33]. The integration of assay imprecision in the outlier definition is therefore, in our opinion, critical. Inclusion criteria were also different across studies. Fleming et al. only included samples with cTnI >100 ng/L along with normal CK [30], while Beyne et al. included all range of cTnI concentrations [34] and Warner et al. [3] samples with a discordance with another platform (Ortho Vitros). Noteworthy, Kazmierczak et al. noticed that the occurrence of these non-reproducible results was not specific to a particular reagent lot [22]. Sheehan et al. also found that two distinct reagent lots were both impacted by outliers [20].

Considering the large difference in analytical performances and measured results among hs-cTnI and hs-cTnT methods [35, 36], it is not surprising that a large dishomogeneity in outlier frequency have been reported in the literature. Of interest, Lee et al. identified a higher outlier rate with a cTnI assay (0.97%) compared to a hs-cTnI assay (0.09%) [27]. More recently, Karon et al. confirmed that a hs-cTnI assay had a lower outlier rate (0.47%) compared to cTnI assay (3.66%). However, the outlier rate of the hs-cTnI assay was not statistically different compared to a cTnT assay [26]. The use of fixed or sex-specific cut-offs modified the number of outliers [26]. If we focus our analysis on studies published since 2010 that used one of the three main outlier definitions, the outlier prevalence is overall lower in high-sensitive assays compared to previous generation assays (Table 3).

## Identification through repeat testing

Studies that used the repeat testing method (i.e., without recentrifugation) to identify outliers are presented in Table 2. Grossly, the outlier rate varied from 0.0 to 34.48% in serum and from 0.10 to 2.0% in plasma. Included

numbers of samples were far higher as compared to studies having used recentrifugation. Favresse et al. included up to 1,243 samples [2], Pretorius et al. 2,391 samples [23], Pretorius et al. 4,336 samples [29], Ryan et al. up to 4,009 samples [24], Sheehan et al. 4,850 samples [20], Ungerer et al. up to 5,265 samples [12], and Sawyer et al. up to 7,089 [13].

Inclusion criteria and outlier definition varied also greatly across studies. The z value definition was used in the study of Pretorius et al. [23, 29], while Ungerer et al. [12], Favresse et al. [2], Ryan et al. [24], and Sawyer et al. [13] used the CD definition. Sawyer et al. found that the hs-cTnI assay was less affected than contemporary cTnI assays for critical outliers [13]. Using the hs-cTnT method, Pretorius et al. found two outliers above the 99th percentile cut-off out of 2,391 duplicate samples (outlier rate = 0.08%;  $z > 3.48$ ) [23]. This outlier rate was significantly lower compared to previous generation assays [23]. However, Ryan et al. found that the outlier rate was not different between the hs-cTnI assay and the contemporary cTnI assay they previously used [24]. In studies published since 2010 and using one of the three main outlier definitions, the outlier prevalence is overall lower in high-sensitive assays compared to previous generation assays (Table 3). Interestingly, Sawyer et al. showed that a lower outlier rate was observed following a full maintenance of their platform [13]. Additionally, Kavsak et al. suggested that other factors contributing to variability may include periods of inactivity of the analyzer as well as the reagent pack sizes [37]. No outlier was classified as a critical outlier in their study.

In our recent report, we showed that the outlier rate varied among two reagent lots used (hs-cTnT). An outlier rate of 3.22 and of 0% was observed on two different and consecutive reagent lots (429178 and 460113). The high outlier rate observed on the first reagent lot was due to contamination with magnetic/paramagnetic particles [2]. Further using the lot 460113 between March 28 and June 6, 2020 (1,998 samples requests for cTn), we encountered two outliers (19.6 to 48.5 and 67.7 to 4.4 ng/L) out of 999 samples analyzed in duplicate. Therefore, the updated outlier rate was 0.093% (4/2,159) and the release of the new reagent lot drastically decreases the occurrence of outliers (Figure 1). On June 7, we installed a new reagent lot (470034). Between June 7 and September 23, we analyzed 1,438 cTn samples in duplicate and four outliers were observed (17.0 to 4.0, 39.8 to 22.7, 42.3 to 10.8, and 28.0 to 3.7 ng/L), leading to an outlier rate of 0.28% (Figure 1). On October 13, we installed a new reagent lot (474941). Between October 13 and December 16, we analyzed 1,748 cTn

Table 1: Summary of studies having identify outliers by recentrifugation.

Reference	Sample type	Troponin	Platform	Included samples	Outlier definition	Outlier rate, %	Nature	Comment
Roberts et al. 1997 [46]	Serum	cTnI	Stratus II (Dade International)	1,200	Clear difference, normal CK-MB and ECG. No previous cTnI increase	2/1,200 (0.17%)	Fibrin <sup>a</sup>	Use of plasma eliminated these outliers
Nosanchuk et al. 1999 [47]	Serum	cTnI	AxSYM (Abbott Diagnostics)	8	Clear difference and consistent with plasma results	NA	Fibrin <sup>a</sup>	Repeat testing not useful
Beyne et al. 2000 [34]	Serum	cTnI	Access (Beckman Coulter)	64	Clear difference	6/64 (9.38%)	Fibrin/microparticles <sup>a</sup>	
Fleming et al. 2002 [30]	Serum	cTnI	Access (Beckman Coulter)	56 (cTnI > 100 ng/L, Normal CK)	Difference of $\pm 2$ SD	16/56 (28.57%)	Fibrin/microparticles <sup>a</sup>	
Sheehan et al. 2002 [20]	Plasma	cTnI	ACS:180 (Bayer Diagnostics)	20	Clear difference	NA	Fibrin	Fibrin added in samples
Kazmierczak et al. 2005 [22]	Serum	cTnI	AxSYM (Abbott Diagnostics)	307 (cTnI > 2,000 ng/L and/or visible fibrin/microparticles)	Difference of 45%	24/307 (7.82%)	Visible fibrin (n=7)	Use of plasma eliminated these outliers
Er et al. 2006 [48]	Serum	cTnI	Access (Beckman Coulter)	6	Clear difference and consistent with plasma results	NA	Fibrin <sup>a</sup>	
Hejl et al. 2008 [32]	Plasma	cTnI	Dxl 800 (Beckman Coulter)	478 (cTnI > 100 ng/L)	Below < 100 ng/L after recentrifugation	17/478 (3.56%)	Fibrin <sup>a</sup>	Recentrifuged at 2,300 g, 15 min
	Plasma	cTnI	Dxl 800 (Beckman Coulter)	1,695 (cTnI > 100 ng/L)	Below < 100 ng/L after recentrifugation	19/1,695 (1.12%)	Fibrin <sup>a</sup>	Recentrifuged at 6,700 g, 5 min
Dimeski et al. 2011 [15]	Plasma	cTnI	AccuTnI (Beckman Coulter)	Two (one patient and one pool of two patients)	Clear difference	NA	Fibrin	Insoluble fibrin in samples
Strathmann et al. 2011 [19]	Plasma	cTnI	Dxl 800 (Beckman Coulter)	Not clear (cTnI > 400 ng/L)	Clear difference and consistent with plasma results	2.27% <sup>b</sup>	Microparticles <sup>a</sup>	
Li et al. 2014 [31]	Serum	cTnI	AxSYM (Abbott Diagnostics)	132 (cTnI > 40 ng/L, normal CK-MB and myoglobin)	Difference of 30%	18/132 (13.64%)	Fibrin/microparticles <sup>a</sup>	Insoluble fibrin in samples. AccuTnI+3
Dimeski et al. 2015 [21]	Plasma	cTnI	Access 2 and Dxl 800 (Beckman Coulter)	One (pool)	Clear difference	NA	Fibrin	
Lee et al. 2016 [27]	Plasma	cTnI	Architect i2000 SR (Abbott Diagnostics)	1,239	Critical outlier <sup>c</sup>	12/1,239 (0.97%)	Unknown	
	Plasma	Hs-cTnI	Architect i2000 SR (Abbott Diagnostics)	1,239	Critical outlier <sup>c</sup>	1/1,239 (0.091%)	Unknown	
Warner et al. 2016 [3]	Plasma	Hs-cTnI	Architect i4000SR (Abbott Diagnostics)	50 (hs-cTnI > cutoff but < 12.0 ng/L or 2x times higher on Vitros)	Clear difference	2/50 (4.00%)	Unknown	

Table 1: (continued)

Reference	Sample type	Troponin	Platform	Included samples	Outlier definition	Outlier rate, %	Nature	Comment
Karon et al. 2018 [26]	Serum	cTnT	Roche e411 (Roche Diagnostics)	3,008	Critical outlier <sup>c</sup>	10/3,008 (0.33%)	Unknown	Within 24 h of initial analysis, samples were aliquoted before re-centrifugation and duplicate analysis
	Serum	cTnI	Architecti2000 SR (Abbott Diagnostics)	3,008	Critical outlier <sup>c</sup>	110/3,008 (3.66%)	Unknown	Within 24 h of initial analysis, samples were aliquoted before re-centrifugation and duplicate analysis
	Serum	Hs-cTnI	Architecti2000 SR (Abbott Diagnostics)	3,008	Critical outlier <sup>c</sup>	14/3,008 (0.47%)	Unknown	Within 24 h of initial analysis, samples were aliquoted before re-centrifugation and duplicate analysis

<sup>a</sup>Hypothesis. <sup>b</sup>Number of total samples not known. <sup>c</sup>Outlier that could potentially have affected the clinical decision (i.e., first cTn result > cut-off and second cTn result < cut-off). Units have been harmonized (ng/L) for clarity. CK-MB, creatine kinase-MB isoenzyme; ECG, electrocardiogram.

samples in duplicate and two outliers were observed (25.6 to 6.4 and 15.8 to 6.5 ng/L), leading to an outlier rate of 0.11% (Figure 1). These latter outlier rates were close to the one published by Pretorius et al. using a hs-cTnT assay [23].

## Discussion

Outliers have been described in all cTn methods and it is strictly related to assay performance. Outliers occur randomly and can produce both false positive and negative results (14). The outlier rate vary according to the outlier definition used (i.e., critical outlier, z value [ $z=3.29, 3.48, \dots$ ]), to the samples included (i.e., random samples, positive cTn results, samples with negative CK-MB results, serum vs. plasma, storage conditions, delay before reanalysis), to the procedure used to identify outliers (i.e., repeat testing or recentrifugation) and to the platform considered (including reagent lots). The direct comparison of studies is therefore difficult. The use of a repeat testing strategy in clinical practice is more convenient than recentrifugation (extra manipulation and TAT). Furthermore, recentrifugation might have an impact on the measurand as warned by the Clinical and Laboratory Standard Institute. Indeed, Canovi et al. showed a median reduction of 10.0 ng/L following recentrifugation [38]. The stability of cTn during a second centrifugation process and a possible increased adherence to the container cannot be excluded [33]. Third, some studies show that recentrifugation had no added value compared to repeat testing to identify outliers [12, 23].

We also focused our analysis on recent studies (i.e., published since 2010) to assess the outlier prevalence of previous and new generation assays (i.e., high-sensitive assays). The outlier definitions included were the most used ones (exceeding a z score value, CD or critical outlier). The outlier prevalence is overall lower in high-sensitive assays (0.28–0.57%) compared to previous generation assays (0.33–1.65%) (Table 3). In contrast to outliers, the biotin interference in cTn assays has received much more attention in the literature since the U.S. Food and Drug Administration notified a death attributable to a false rule-out of MI based on a falsely decreased cTn result. However, the prevalence of biotin >20.0 ng/mL in real-life studies was found to be 0% (0/572) and 0.13% (1/797) [39, 40]. Furthermore, the misclassification risk due to biotin interference was even lower (0.025, 0.0064, 0.00048%, and <0.00001% at 0, 1, 3, and 6 h) [40]. The prevalence of cTn outliers is therefore higher (Table 3). To limit the impact of biotin in cTn assays, manufacturers have added blockers that successfully overcame the interference up to 1,200 ng/mL [11]. The prevalence of heterophilic antibodies

Table 2: Summary of studies having identify outliers by repeat testing.

Reference	Sample type	Troponin	Platform	Included samples	Outlier definition	Outlier rate, %	Nature	Comment
Sheehan et al. 2002 [20]	Plasma	cTnl	ACS:180 (Bayer Diagnostics)	4,850	CV > 20% and absolute difference > 160 ng/L	19/4,850 (0.39%)	Visible fibrin/microparticles/clot sample (n=6)	
Ungerer et al. 2010 [12]	Serum and plasma	cTnl	Access 2 and Dxl 800 (Beckman Coulter)	5,265 (cTnl > 40 ng/L)	Critical difference <sup>b</sup>	102/5,265 (1.94%)	Unknown	First evaluation (six months)
	Serum	cTnl	Access 2 and Dxl 800 (Beckman Coulter)	419	Critical difference <sup>b</sup>	6/419 (1.43%)	Unknown	Second evaluation (one month)
Dimeski et al. 2011 [15]	Plasma	cTnl	Access 2 and Dxl 800 (Beckman Coulter)	462	Critical difference <sup>b</sup>	5/462 (1.08%)	Unknown	Second evaluation (one month)
Pretorius et al. 2011 [23]	Serum	cTnl	Access 2 (Beckman Coulter)	Two (including one pool of two patients)	Clear difference	NA	Fibrin	Insoluble fibrin in samples
	Serum	cTnl	Access 2 (Beckman Coulter)	2,391	z value <sup>c</sup> > 3.48 with (a) IQC SD, (b) duplicate SD, (c) constant SD equivalent to 10% CV	(a) 21 (0.88%), (b) 30 (1.25%), (c) 19/2,391 (0.79%)	Fibrin <sup>a</sup>	
	Serum	cTnl	ADVIA Centaur XP (Siemens)	2,391	z value <sup>c</sup> > 3.48 with (a) IQC SD, (b) duplicate SD, (c) constant SD equivalent to 10% CV	(a) 5 (0.21%), (b) 35 (1.46%), (c) 11/2,391 (0.46%)	Fibrin <sup>a</sup>	
	Serum	cTnl	Architect i2000SR (Abbott Diagnostics)	2,391	z value <sup>c</sup> > 3.48 with (a) IQC SD, (b) duplicate SD, (c) constant SD equivalent to 10% CV	(a) 5 (0.21%), (b) 6 (0.25%), (c) 4/2,391 (0.17%)	Fibrin <sup>a</sup>	
	Serum	Hs-cTnT	Cobas e601 (Roche Diagnostics)	2,391	z value <sup>c</sup> > 3.48 with (a) IQC SD, (b) duplicate SD, (c) constant SD equivalent to 10% CV	(a) 3 (0.13%), (b) 11 (0.46%), (c) 1/2,391 (0.04%)	Fibrin <sup>a</sup>	
Kavsak et al. 2014 [37]	Plasma	cTnl	Architect (Abbott Diagnostics)	One (low patient pool)	Clear difference	NA	Reagent pack (following an inactivity period)	From 100-test reagent pack to 500
Ryan et al. 2014 [24]	Plasma	cTnl	Architect i2000SR (Abbott Diagnostics)	4,009 (cTnl 30–300.0 ng/L)	(a) Critical difference <sup>b</sup> and (b) critical outlier <sup>d</sup>	(a) 9/4,009 (0.22%) and (b) 4/4,009 (0.10%)	Unknown	
	Plasma	Hs-cTnl	Architect i2000SR (Abbott Diagnostics)	3,878 (hs-cTnl 16–300.0 ng/L)	(a) Critical difference <sup>b</sup> and (b) critical outlier <sup>d</sup>	(a) 7/3,878 (0.18%) and (b) 5/3,878 (0.13%)	Unknown	
Sawyer et al. 2014 [13]	Serum	cTnl	Architect i2000SR (Abbott Diagnostics)	7,011	(a) Critical difference <sup>b</sup> and (b) critical outlier <sup>d</sup>	(a) 137 (1.95%) and (b) 36/7,011 (0.51%)	Unknown	Before full maintenance
	Serum	cTnl	Architect i2000SR (Abbott Diagnostics)	7,089	(a) Critical difference <sup>b</sup> and (b) critical outlier <sup>d</sup>	(a) 34 (0.48%) and (b) 26/7,089 (0.37%)	Unknown	After full maintenance
	Serum	Hs-cTnl	Architect i2000SR (Abbott Diagnostics)	1,522	(a) Critical difference <sup>b</sup> and (b) critical outlier <sup>d</sup>	(a) 9 (0.59%) and (b) 0/1,522 (0%)	Unknown	
	Plasma	cTnl		One (pool)	Clear difference	NA	Fibrin	




Table 2: (continued)

Reference	Sample type	Troponin	Platform	Included samples	Outlier definition	Outlier rate, %	Nature	Comment
Dimeski et al. 2015 [21]	Serum	cTnI	Access 2 and Dxl 800 (Beckman Coulter)	29 (cTnI > 30.0 ng/L)	Clear difference	10/29 (34.48%)	Unknown	Insoluble fibrin in samples. AccuTnI+3 Healthy volunteers
Greene et al. 2015 [25]	Plasma	cTnI	Access 2 (Beckman Coulter)	50	>3.5 (z value) x $z^{0.5} \times (CV_A^2 + CV_P^2) = 23.1\%$	1/50 (2.0%)	Unknown	Samples enriched with native full-length cTnI protein
Loh et al. 2016 [28]	Serum	Hs-cTnI	Vitros TnI ES (Ortho Clinical Diagnostics)	4,336	z value <sup>c</sup> > 3.5	2/4,336 (0.046%)	Unknown	
Pretorius et al. 2018 [29]	Plasma	cTnT	Access (Beckman Coulter)	17,154 <sup>e</sup>	(a) initial and repeat values differing by >±5 ng/L (cTnT <100 ng/L) or ±5% cTnT ≥100 ng/L and (b) if (a) and abnormal/normal to normal/abnormal	(a) 19 (0.11%) and (b) 8//17,154 (0.05%)	Unknown	
Wockenfus et al. 2019 [49]	Serum	Hs-cTnT	Cobas 411 (Roche Diagnostics)	1,243	(a) Critical difference <sup>b</sup> and (b) critical outlier <sup>d</sup>	(a) 40 (3.22%) and (b) 17/1,253 (1.37%)	Contamination with magnetic/paramagnetic microparticles	Reagent lot 1 [2]
Favresse et al. 2020 [2]	Serum	Hs-cTnT	Cobas e801 (Roche Diagnostics)	>14.0 ng/L	(a) Critical difference <sup>b</sup> and (b) critical outlier <sup>d</sup>	(a) 0 (0%) and (b) 0/1,160 (0%)	NA	Reagent lot 2 [2]
	Serum	Hs-cTnT	Cobas e801 (Roche Diagnostics)	1,160 (hs-cTnT >14.0 ng/L)	(a) Critical difference <sup>b</sup> and (b) critical outlier <sup>d</sup>	(a) 2 (0.20%) and (b) 1/999 (0.1%)	Contamination?	Reagent lot 2 (second part)
	Serum	Hs-cTnT	Cobas e801 (Roche Diagnostics)	999 (hs-cTnT >14.0 ng/L)	(a) Critical difference <sup>b</sup> and (b) critical outlier <sup>d</sup>	(a) 2 (0.17%) and (b) 1/1,148 (0.09%)	Contamination?	Reagent lot 3
	Serum	Hs-cTnT	Cobas e801 (Roche Diagnostics)	1,148 (hs-cTnT >14.0 ng/L)	(a) Critical difference <sup>b</sup> and (b) critical outlier <sup>d</sup>	(a) 2 (0.69%) and (b) 2/290 (0.69%)	Contamination?	Reagent lot 3
	Serum	Hs-cTnT	Cobas e801 (Roche Diagnostics)	290 (hs-cTnT >14.0 ng/L)	(a) Critical difference <sup>b</sup> and (b) critical outlier <sup>d</sup>	(a) 2 (0.11%) and (b) 2/1,748 (0.11%)	Contamination?	Reagent lot 4

<sup>a</sup>Hypothesis. <sup>b</sup>z value (result 1 – result 2)/√(SD<sub>1</sub><sup>2</sup> + SD<sub>2</sub><sup>2</sup>). <sup>c</sup>Critical difference (z × √2 × SD<sub>Analytical</sub>). <sup>d</sup>Outlier that could potentially have affected the clinical decision (i.e., first cTn result > cut-off and second cTn result < cut-off). CV<sub>P</sub>, coefficient of variation of pipetting procedure. Units have been harmonized (ng/L) for clarity. <sup>e</sup>Not clear if representing the total number of samples analyzed in duplicate or not.

**Table 3:** The mean outlier rate calculated from studies published since 2010 according to the type of cTn assay and to the method to identify outlier.

	Repeat testing		Recentrifugation	
	Critical difference or z value	Critical outlier	Critical difference or z value	Critical outlier
cTnI and cTnT	1.05%	0.33%	NA	1.65%
hs-cTnI and hs-cTnI	0.57%	0.34%	NA	0.28%



**Figure 1:** Rates of outliers observed in Clinique Saint-Luc Bouge using four different hs-cTnT reagent lots.

Dark blue = rate of outliers calculated by the CD formula; purple = rate of critical outliers (i.e., first cTn result > cut-off and second cTn result < cut-off).

in cTn assays has been found to range from 0.07 to 3.0% [21, 41] and manufacturers also add blockers to limit interference due to heterophilic antibodies [5]. The identification of outliers is however more problematic.

A pragmatic solution would be to test every elevated cTn in duplicate to identify outliers. However, such a solution would be costly and significantly increases the TAT. In our laboratory (Saint-Luc Bouge) the prevalence of positive cTn results is about 50%. Testing in duplicate would hence double the reagent cost. In the same way, we suggest that a 1-h (or 3-h) cTn result significantly lower (>30% difference [42]) than the 0-h result (0-h/1-h [or 3-h] algorithm) could be investigated for a potential outlier in patients presenting with symptoms suggestive of acute MI

(including acute chest pain and angina pectoris) [43, 44]. Automatic comments and repeat testing could therefore be generated in the laboratory information system in case of particular cTn kinetics. Continuous discussion between clinicians and the laboratory is fundamental to identify these erroneous and non-reproducible results. We further recommend that manufacturers continuously improve the robustness of their procedures to avoid erroneous cTn results that may potentially lead to harmful consequences for the patient. Given the growing data on the subject, in addition to precision and trueness, the frequency of analytical outliers should be systematically evaluated before the implementation of a new cTn assay. We therefore also encourage manufacturers, in collaboration with clinical laboratories and regulatory bodies, to conduct large studies to assess the occurrence of these outliers and to provide the probability of outliers using their assays. These evaluations could be performed for cTn but also for other measurands for which outliers have also been identified [45].

## Conclusions

The outliers described in the literature for cTn measurement occurred randomly, sometimes frequently, were non-reproducible, and could not be explained by imprecision of the analyzer. Simple repeat testing of the original sample represents the best way to identify these outliers. Clinicians need to have an ongoing dialog with laboratory professionals in case of discordance with the clinical presentation to prevent harmful clinical consequences. We further recommend that manufacturers continuously improve the robustness of their procedures to avoid erroneous cTn results that may potentially lead to harmful consequences for the patient.

**Research funding:** None declared.

**Author contributions:** All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

**Competing interests:** Authors state no conflict of interest.

## References

1. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). *Eur Heart J* 2019;40:237–69.
2. Favresse J, Cadrobbi J, Eucher C, Laffineur K, Rosseels C, Pieters D, et al. Non-reproducible cardiac troponin results occurring with a particular reagent lot. *Clin Chem Lab Med* 2020;59:e9–e12.

3. Warner JV, Marshall GA. High incidence of macrotroponin I with a high-sensitivity troponin I assay. *Clin Chem Lab Med* 2016;54:1821–9.
4. Dalle Carbonare L, Pizzini M, Micheletti V, Lo Cascio C, Bovo C, Girelli D, et al. Interference from immunocomplexes on a high-sensitivity cardiac troponin T immunoassay. *Clin Chem Lab Med* 2020;58:e225–7.
5. Lippi G, Aloe R, Meschi T, Borghi L, Cervellin G. Interference from heterophilic antibodies in troponin testing. Case report and systematic review of the literature. *Clin Chim Acta* 2013;426:79–84.
6. Herman DS, Ranjitkar P, Yamaguchi D, Grenache DG, Greene DN. Endogenous alkaline phosphatase interference in cardiac troponin I and other sensitive chemiluminescence immunoassays that use alkaline phosphatase activity for signal amplification. *Clin Biochem* 2016;49:1118–21.
7. Lin CT, Lee HC, Voon WC, Yen HW, Tang MH, Chin TT, et al. Positive interference from contrast media in cardiac troponin I immunoassays. *Kaohsiung J Med Sci* 2006;22:107–13.
8. Galambos C, Brink DS, Ritter D, Chung HD, Creer MH. False-positive plasma troponin I with the AxSYM analyzer. *Clin Chem* 2000;46:1014–5.
9. Wilgen U, Pretorius CJ, Gould MJ, Ungerer JP. Cardiac Troponin I carryover by very high patient samples still causes false-positive results on the Beckman Coulter AccuTnl + 3. *Ann Clin Biochem* 2016;53:177–9.
10. Clerico A, Plebani M. Biotin interference on immunoassay methods: sporadic cases or hidden epidemic? *Clin Chem Lab Med* 2017;55:777–9.
11. Mzougui S, Favresse J, Soleimani R, Fillee C, Gruson D. Biotin interference: evaluation of a new generation of electrochemiluminescent immunoassays for high-sensitive troponin T and thyroid-stimulating hormone testing. *Clin Chem Lab Med* 2020;58:2037–45.
12. Ungerer JP, Pretorius CJ, Dimeski G, O'Rourke PK, Tyack SA. Falsely elevated troponin I results due to outliers indicate a lack of analytical robustness. *Ann Clin Biochem* 2010;47:242–7.
13. Sawyer N, Blennerhassett J, Lambert R, Sheehan P, Vasikaran SD. Outliers affecting cardiac troponin I measurement: comparison of a new high sensitivity assay with a contemporary assay on the Abbott ARCHITECT analyser. *Ann Clin Biochem* 2014;51:476–84.
14. Clerico A, Belloni L, Carrozza C, Correale M, Dittadi R, Dotti C, et al. A Black Swan in clinical laboratory practice: the analytical error due to interferences in immunoassay methods. *Clin Chem Lab Med* 2018;56:397–402.
15. Dimeski G. Evidence on the cause of false positive troponin I results with the Beckman AccuTnl method. *Clin Chem Lab Med* 2011;49:1079–80.
16. Lima-Oliveira G, Monneret D, Guerber F, Guidi GC. Sample management for clinical biochemistry assays: are serum and plasma interchangeable specimens? *Crit Rev Clin Lab Sci* 2018;55:480–500.
17. Dimeski G, Masci PP, Trabi M, Lavin MF, de Jersey J. Evaluation of the Becton-Dickinson rapid serum tube: does it provide a suitable alternative to lithium heparin plasma tubes? *Clin Chem Lab Med* 2010;48:651–7.
18. Simundic AM, Bolenius K, Cadamuro J, Church S, Cornes MP, van Dongen-Lases EC, et al. Joint EFLM-COLABIOCLI Recommendation for venous blood sampling. *Clin Chem Lab Med* 2018;56:2015–38.
19. Strathmann FG, Ka MM, Rainey PM, Baird GS. Use of the BD vacutainer rapid serum tube reduces false-positive results for selected beckman coulter Unicl Dxl immunoassays. *Am J Clin Pathol* 2011;136:325–9.
20. Sheehan P, Blennerhassett J, Vasikaran SD. Decision limit for troponin I and assay performance. *Ann Clin Biochem* 2002;39:231–6.
21. Dimeski G, Coogan M, Jones B, Brown N. Is the new Beckman AccuTnl+3 assay capable of producing false-positive troponin I results? *Clin Chem Lab Med* 2015;53:e101–3.
22. Kazmierczak SC, Sekhon H, Richards C. False-positive troponin I measured with the Abbott AxSYM attributed to fibrin interference. *Int J Cardiol* 2005;101:27–31.
23. Pretorius CJ, Dimeski G, O'Rourke PK, Marquart L, Tyack SA, Wilgen U, et al. Outliers as a cause of false cardiac troponin results: investigating the robustness of 4 contemporary assays. *Clin Chem* 2011;57:710–8.
24. Ryan JB, Southby SJ, Stuart LA, Mackay R, Florkowski CM, George PM. Comparison of cardiac Tnl outliers using a contemporary and a high-sensitivity assay on the Abbott Architect platform. *Ann Clin Biochem* 2014;51:507–11.
25. Greene DN, Holmes DT, Liang J, Kwong SL, Lorey TS, Petrie MS. Challenges in harmonizing integrated healthcare network laboratories: multi-center evaluation of the AccuTnl+3 troponin assay. *Clin Biochem* 2015;48:268–74.
26. Karon BS, Wockenfus AM, Hartung KJ, Scott RJ, Carter SD, Jaffe AS. Comparing analytical outliers and the percent of emergency department patients with results above the 99th percentile upper reference limit for 2 conventional and one high sensitivity troponin assay. *Clin Biochem* 2018;53:104–9.
27. Lee GR, Browne TC, Guest B, Khan I, Murphy E, McGorrian C, et al. Transitioning high sensitivity cardiac troponin I (hs-cTnl) into routine diagnostic use: more than just a sensitivity issue. *Pract Lab Med* 2016;4:62–75.
28. Loh TP, Lim XC, Kieu K, Sajiir H, Neo SF, Cheng WL, et al. Recovery of spiked troponin I in four routine assays. *Biochem Med* 2016;26:233–9.
29. Pretorius CJ, Tate JR, Wilgen U, Cullen L, Ungerer JP. A critical evaluation of the Beckman Coulter Access hsTnl: analytical performance, reference interval and concordance. *Clin Biochem* 2018;55:49–55.
30. Fleming SM, O'Byrne L, Finn J, Grimes H, Daly KM. False-positive cardiac troponin I in a routine clinical population. *Am J Cardiol* 2002;89:1212–5.
31. Li Y, Wang X, Xu L, Wen X. Rapid identification of falsely elevated serum cardiac troponin I values in a stat laboratory. *Lab Med* 2014;45:82–5.
32. Hejl CG, Astier HT, Ramirez JM. Prevention of preanalytical false-positive increases of cardiac troponin I on the Unicl Dxl 800 analyzer. *Clin Chem Lab Med* 2008;46:1789–90.
33. Pfafflin A. Doubt on prevention of false-positive results of cardiac troponin I by recentrifugation. *Clin Chem Lab Med* 2009;47:892–3.
34. Beyne P, Vigier JP, Bourgoin P, Vidaud M. Comparison of single and repeat centrifugation of blood specimens collected in BD evacuated blood collection tubes containing a clot activator for cardiac troponin I assay on the ACCESS analyzer. *Clin Chem* 2000;46:1869–70.
35. Clerico A, Zaninotto M, Padoan A, Masotti S, Musetti V, Prontera C, et al. Evaluation of analytical performance of immunoassay methods for cTnl and cTnT: from theory to practice. *Adv Clin Chem* 2019;93:239–62.

36. Clerico A, Ripoli A, Zaninotto M, Masotti S, Musetti V, Ciaccio M, et al. Head-to-head comparison of plasma cTnI concentration values measured with three high-sensitivity methods in a large Italian population of healthy volunteers and patients admitted to emergency department with acute coronary syndrome: a multicenter study. *Clin Chim Acta* 2019;496:25–34.
37. Kavsak PA, Clark L, Lancaster S, Don-Wauchope AC. Within-run precision and outlier detection for the Abbott ARCHITECT cardiac troponin I assay. *Ann Clin Biochem* 2014;51:512–4.
38. Canovi S, Campioli D, Marcheselli L. Specimen recentrifugation and elevated troponin I levels. *Lab Med* 2015;46:47–50.
39. Vroemen WHM, van Doorn W, Kimenai DM, Wodzig W, de Boer D, Bekers O, et al. Biotin interference in high-sensitivity cardiac troponin T testing: a real-world evaluation in acute cardiac care. *Cardiovasc Res* 2019;115:1950–1.
40. Mumma B, Diercks D, Twerenbold R, Valcour A, Ziegler A, Schützenmeister A, et al. Clinical risk assessment of biotin interference with a high-sensitivity cardiac troponin T assay. *Clin Chem Lab Med* 2020;58:1931–40.
41. Herman DS, Kavsak PA, Greene DN. Variability and error in cardiac troponin testing: an ACLPS critical review. *Am J Clin Pathol* 2017;148:281–95.
42. Clerico A, Padoan A, Zaninotto M, Passino C, Plebani M. Clinical relevance of biological variation of cardiac troponins. *Clin Chem Lab Med* 2020;59:641–52.
43. Mueller C, Giannitsis E, Christ M, Ordonez-Llanos J, deFilippi C, McCord J, et al. Multicenter evaluation of a 0-hour/1-hour algorithm in the diagnosis of myocardial infarction with high-sensitivity cardiac troponin T. *Ann Emerg Med* 2016;68:76–87.e4.
44. Neumann JT, Sorensen NA, Schwemer T, Ojeda F, Bourry R, Sciacca V, et al. Diagnosis of myocardial infarction using a high-sensitivity troponin I 1-hour algorithm. *JAMA Cardiol* 2016;1:397–404.
45. Neubig S, Grotevendt A, Kallner A, Nauck M, Petersmann A. Analytical robustness of nine common assays: frequency of outliers and extreme differences identified by a large number of duplicate measurements. *Biochem Med* 2017;27:192–8.
46. Roberts WL, Calcote CB, De BK, Holmstrom V, Narlock C, Apple FS. Prevention of analytical false-positive increases of cardiac troponin I on the Stratus II analyzer. *Clin Chem* 1997;43:860–1.
47. Nosanchuk JS, Combs B, Abbott G. False increases of troponin I attributable to incomplete separation of serum. *Clin Chem* 1999;45:714.
48. Er TK, Tsai LY, Jong YJ, Chen BH. Falsely elevated troponin I attributed to inadequate centrifugation using the Access immunoassay analyzer. *Clin Chem Lab Med* 2006;44:908–9.
49. Wockenfus A, Hartung K, Kelley B, Katzman B, Donato L, Jaffe A, et al. Real-time detection of analytical outliers on the Roche troponin T generation 5 assay. *Am J Clin Pathol* 2019;152:S83.